Baird Cuts Price Target on Regeneron (REGN) as Late Stage Trials Hit Operating Costs - Reiterates Outperform

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. GOOGL
6. APGE
7. DFTX
8. MU
9. IBM
10. HOOD

Go back to Baird Cuts Price Target on Regeneron (REGN) as Late Stage Trials Hit Operating Costs - Reiterates Outperform

Regeneron Reports Fourth Quarter and Full Year 2015 Financial and Operating Results

February 9, 2016 6:31 AM EST

TARRYTOWN, N.Y., Feb. 9, 2016 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the fourth quarter and full year 2015 and provided an update on development programs.

Financial Highlights

($ in millions, except per share data)

Three Months Ended

December... More